Stay updated on SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Sign up to get notified when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.

Latest updates to the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedPage metadata updated to Revision: v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check15 days agoChange DetectedAdded new collaborators/institutions (Henry Ford Cancer Institute, New York University, University of Michigan) and Merck Sharp & Dohme LLC to the study record. Included a link to the SPRINT publication in The Journal of Clinical Oncology and introduced a Study Results section with revision v3.4.3.SummaryDifference0.7%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedAdded Revision: v3.4.2 and removed the prior government funding/operating status notice (v3.4.1). These changes are site-wide maintenance updates and do not affect the study details on the page.SummaryDifference0.4%

- Check51 days agoChange DetectedA government funding notice was added to inform users about potential disruptions and where to check status updates. The site revision tag was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check58 days agoChange DetectedAdded a glossary toggle and a new revision reference (v3.4.0). Updated capitalization and wording for QC criteria labeling and the FEAR Act data line, and removed the older v3.3.4 reference.SummaryDifference0.2%

- Check72 days agoChange DetectedThe page shows Revision: v3.3.4 (replacing v3.3.3), indicating a minor update with no changes to study details.SummaryDifference0.1%

Stay in the know with updates to SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.